vs
Side-by-side financial comparison of HighPeak Energy, Inc. (HPK) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($311.4M vs $216.6M, roughly 1.4× HighPeak Energy, Inc.). Bio-Techne runs the higher net margin — 16.4% vs -11.6%, a 28.0% gap on every dollar of revenue. On growth, Bio-Techne posted the faster year-over-year revenue change (-1.5% vs -23.3%). Over the past eight quarters, Bio-Techne's revenue compounded faster (1.3% CAGR vs -13.2%).
Duke Energy Corporation is an American electric power and natural gas holding company headquartered in Charlotte, North Carolina. The company serves over 7 million customers in the eastern United States. In 2024 it ranked as the 141st largest company in the United States – its highest-ever placement on the Fortune 500 list.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
HPK vs TECH — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $216.6M | $311.4M |
| Net Profit | $-25.2M | $51.0M |
| Gross Margin | — | 66.9% |
| Operating Margin | -7.6% | 24.2% |
| Net Margin | -11.6% | 16.4% |
| Revenue YoY | -23.3% | -1.5% |
| Net Profit YoY | -380.7% | 126.0% |
| EPS (diluted) | $-0.16 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $311.4M | ||
| Q4 25 | $216.6M | $295.9M | ||
| Q3 25 | $188.9M | — | ||
| Q2 25 | $200.4M | $317.0M | ||
| Q1 25 | $257.4M | $316.2M | ||
| Q4 24 | $282.6M | $297.0M | ||
| Q3 24 | $271.6M | $289.5M | ||
| Q2 24 | $275.3M | $306.1M |
| Q1 26 | — | $51.0M | ||
| Q4 25 | $-25.2M | $38.0M | ||
| Q3 25 | $-18.3M | — | ||
| Q2 25 | $26.2M | $-17.7M | ||
| Q1 25 | $36.3M | $22.6M | ||
| Q4 24 | $9.0M | $34.9M | ||
| Q3 24 | $49.9M | $33.6M | ||
| Q2 24 | $29.7M | $40.6M |
| Q1 26 | — | 66.9% | ||
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% |
| Q1 26 | — | 24.2% | ||
| Q4 25 | -7.6% | 18.4% | ||
| Q3 25 | 17.3% | — | ||
| Q2 25 | 21.7% | -7.5% | ||
| Q1 25 | 35.1% | 12.2% | ||
| Q4 24 | 26.1% | 16.0% | ||
| Q3 24 | 27.0% | 13.8% | ||
| Q2 24 | 31.7% | 15.0% |
| Q1 26 | — | 16.4% | ||
| Q4 25 | -11.6% | 12.8% | ||
| Q3 25 | -9.7% | — | ||
| Q2 25 | 13.1% | -5.6% | ||
| Q1 25 | 14.1% | 7.1% | ||
| Q4 24 | 3.2% | 11.7% | ||
| Q3 24 | 18.4% | 11.6% | ||
| Q2 24 | 10.8% | 13.3% |
| Q1 26 | — | $0.32 | ||
| Q4 25 | $-0.16 | $0.24 | ||
| Q3 25 | $-0.15 | — | ||
| Q2 25 | $0.19 | $-0.11 | ||
| Q1 25 | $0.26 | $0.14 | ||
| Q4 24 | $0.06 | $0.22 | ||
| Q3 24 | $0.35 | $0.21 | ||
| Q2 24 | $0.21 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $162.1M | $209.8M |
| Total DebtLower is stronger | $1.2B | — |
| Stockholders' EquityBook value | $1.6B | $2.1B |
| Total Assets | $3.2B | $2.6B |
| Debt / EquityLower = less leverage | 0.75× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $209.8M | ||
| Q4 25 | $162.1M | $172.9M | ||
| Q3 25 | $164.9M | — | ||
| Q2 25 | $21.9M | $162.2M | ||
| Q1 25 | $51.6M | $140.7M | ||
| Q4 24 | $86.6M | $177.5M | ||
| Q3 24 | $135.6M | $187.5M | ||
| Q2 24 | $157.9M | $152.9M |
| Q1 26 | — | — | ||
| Q4 25 | $1.2B | $260.0M | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.0B | $346.0M | ||
| Q1 25 | $1.0B | $330.0M | ||
| Q4 24 | $1.0B | $300.0M | ||
| Q3 24 | $1.1B | $300.0M | ||
| Q2 24 | $1.1B | $319.0M |
| Q1 26 | — | $2.1B | ||
| Q4 25 | $1.6B | $2.0B | ||
| Q3 25 | $1.6B | — | ||
| Q2 25 | $1.7B | $1.9B | ||
| Q1 25 | $1.6B | $2.0B | ||
| Q4 24 | $1.6B | $2.1B | ||
| Q3 24 | $1.6B | $2.1B | ||
| Q2 24 | $1.6B | $2.1B |
| Q1 26 | — | $2.6B | ||
| Q4 25 | $3.2B | $2.5B | ||
| Q3 25 | $3.2B | — | ||
| Q2 25 | $3.1B | $2.6B | ||
| Q1 25 | $3.1B | $2.6B | ||
| Q4 24 | $3.1B | $2.7B | ||
| Q3 24 | $3.1B | $2.7B | ||
| Q2 24 | $3.1B | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | 0.75× | 0.13× | ||
| Q3 25 | 0.73× | — | ||
| Q2 25 | 0.62× | 0.18× | ||
| Q1 25 | 0.63× | 0.16× | ||
| Q4 24 | 0.65× | 0.14× | ||
| Q3 24 | 0.67× | 0.14× | ||
| Q2 24 | 0.70× | 0.15× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $93.1M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $93.1M | — | ||
| Q3 25 | $120.2M | — | ||
| Q2 25 | $141.2M | $98.2M | ||
| Q1 25 | $157.1M | $41.1M | ||
| Q4 24 | $139.5M | $84.3M | ||
| Q3 24 | $177.1M | $63.9M | ||
| Q2 24 | $202.3M | $75.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $93.3M | ||
| Q1 25 | — | $31.0M | ||
| Q4 24 | — | $77.5M | ||
| Q3 24 | — | $54.7M | ||
| Q2 24 | — | $57.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 29.4% | ||
| Q1 25 | — | 9.8% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | — | 18.9% | ||
| Q2 24 | — | 18.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 3.2% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 3.2% | ||
| Q2 24 | — | 5.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 5.39× | — | ||
| Q1 25 | 4.32× | 1.82× | ||
| Q4 24 | 15.53× | 2.42× | ||
| Q3 24 | 3.55× | 1.90× | ||
| Q2 24 | 6.81× | 1.86× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HPK
| Crude Oil Sales | $152.1M | 70% |
| Natural Gas And NGL Sales | $60.8M | 28% |
TECH
| Protein Sciences segment revenue | $226.2M | 73% |
| Diagnostics and Spatial Biology segment revenue | $85.6M | 27% |
| Other revenue (1) | $5.4M | 2% |
